BECOME MEMBER SUPPORT
Year Cancer type Speaker
Management of Genitourinary Cancer Revisit ASCO GU - 26 March 2022
Welcome & Introduction
NAT IN MIBC IDEAL DRUG REGIMEN
IMbrave 150 Phase III trial of 1L Atezolizumab + Bevacizumab in patients with unresectable HCC
Video and slides 
CRSF Asco list of publications 
Ongoing studies 